Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...

Rachel*, 30, went to get fitted for a hormonal coil in 2022, the nurse advised her to take co-codamol an hour beforehand ...

Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious opportunities, particularly with ...

Mallinckrodt, the nation’s biggest opioid pill maker, agreed to pay $1.7 billion in opioids damages in 2022 in its first ...

A jury in November ordered the companies to pay $266 million for flooding Baltimore with hundreds of millions of addictive opioid painkillers from 2006 to 2019. Now it’s up to Circuit Judge ...

They found that a drug called N-acetylcysteine (NAC), which is already approved by the FDA for other uses, can help reduce pain and lower the need for opioid painkillers after surgery. This ...

The authors provide convincing data that identify a novel, non-opioid biologic from human birth tissue products with anti-nociceptive properties in a preclinical mouse model of surgical pain. This ...

Naloxone is now available over-the-counter, and is often handed out with prescriptions for opioid painkillers. "A soldier or a trauma doc will tell you the very first thing you need to do is to ...